NEW YORK — It’s not really a stretch of the imagination to think that microbiome companies should care deeply about who will lead the Food and Drug Administration after the current commissioner, Scott Gottlieb, departs in a few weeks. After all, no microbiome-based drug has yet gone through the regulatory process and made it to market and investors are still skittish about how those drugs will be received by the agency.
Yet a five-person panel of microbiome executives on a panel at the inaugural Chardan Microbiome Summit on Thursday didn’t address the shift in leadership until prompted by a member of the audience. And when they did, the response was essentially “meh.”
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
